Literature DB >> 35992759

Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?

Nadine Kronfli1, Jane A Buxton2, Lindsay Jennings3, Fiona Kouyoumdjian4,5, Alexander Wong6.   

Abstract

Approximately 25% of people in Canadian correctional facilities have been previously exposed to hepatitis C virus (HCV). Despite being a high-prevalence setting, most Canadian prisons have thus far failed to engage the majority of those with chronic HCV infection in care. Several factors, including the lack of systematic screening programs, lack of on-site and trained health care personnel to improve access to care and treatment during incarceration, and the absence of standardized procedures needed to facilitate linkage to care following release likely contribute to poor engagement along the HCV care cascade for people in prison. HCV screening and engagement in care for people in prison can be improved through the implementation of universal opt-out screening upon admission and consideration of multidisciplinary care models for the provision of care. As well, the dissemination of prison-based needle and syringe programs to avert new HCV infections and re-infections should be considered. To meet the World Health Organization (WHO) 2030 HCV elimination goals, engaging researchers, clinicians and other health care providers, policy makers, correctional officials, and members of community in dialogue will be an essential first step going forward.
Copyright © 2019 Canadian Association for the Study of the Liver.

Entities:  

Keywords:  HCV micro-elimination; harm reduction; hepatitis C virus; linkage; people in prison; screening; treatment

Year:  2019        PMID: 35992759      PMCID: PMC9202815          DOI: 10.3138/canlivj.2019-0007

Source DB:  PubMed          Journal:  Can Liver J        ISSN: 2561-4444


  67 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Dramatic budget increase for hepatitis treatment in federal prisons.

Authors:  Paul Webster
Journal:  CMAJ       Date:  2017-08-14       Impact factor: 8.262

3.  The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Authors:  Hemant Shah; Marc Bilodeau; Kelly W Burak; Curtis Cooper; Marina Klein; Alnoor Ramji; Dan Smyth; Jordan J Feld
Journal:  CMAJ       Date:  2018-06-04       Impact factor: 8.262

4.  Patient navigators effectively support HIV-infected individuals returning to the community from jail settings.

Authors:  Janet J Myers; Kimberly A Koester; Mi-Suk Kang Dufour; Alison O Jordan; Jacqueline Cruzado-Quinone; Alissa Riker
Journal:  Int J Prison Health       Date:  2017-09-11

5.  Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Authors:  Sarah Kattakuzhy; Chloe Gross; Benjamin Emmanuel; Gebeyehu Teferi; Veronica Jenkins; Rachel Silk; Elizabeth Akoth; Aurielle Thomas; Charisse Ahmed; Michelle Espinosa; Angie Price; Elana Rosenthal; Lydia Tang; Eleanor Wilson; Soren Bentzen; Henry Masur; Shyam Kottilil
Journal:  Ann Intern Med       Date:  2017-08-08       Impact factor: 25.391

6.  A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri B Bazerman; Emily J Patry; Alice Cates; Liem Tran; Amanda Noska; Irene Kuo
Journal:  J Public Health (Oxf)       Date:  2015-03-02       Impact factor: 2.341

7.  Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system.

Authors:  Danica E Kuncio; E Claire Newbern; Marcelo H Fernandez-Viña; Bruce Herdman; Caroline C Johnson; Kendra M Viner
Journal:  J Urban Health       Date:  2015-04       Impact factor: 3.671

8.  Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Authors:  Sarah Kattakuzhy; Eleanor Wilson; Sreetha Sidharthan; Zayani Sims; Mary McLaughlin; Angie Price; Rachel Silk; Chloe Gross; Elizabeth Akoth; Maryellen McManus; Benjamin Emmanuel; Shikha Shrivastava; Lydia Tang; Amy Nelson; Gebeyehu Teferi; Jose Chavez; Brian Lam; Hongmei Mo; Anuoluwapo Osinusi; Michael A Polis; Henry Masur; Anita Kohli; Shyamasundaran Kottilil
Journal:  Clin Infect Dis       Date:  2015-10-26       Impact factor: 9.079

9.  Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.

Authors:  Jack Stone; Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; Esther Aspinall; Avril Taylor; Alison Munro; Karen Dunleavy; Erica Peters; Peter Bramley; Peter C Hayes; David J Goldberg; Peter Vickerman
Journal:  Addiction       Date:  2017-03-03       Impact factor: 6.526

10.  A prospective controlled trial of routine opt-out HIV testing in a men's jail.

Authors:  Ravi Kavasery; Duncan Smith-Rohrberg Maru; Laurie N Sylla; David Smith; Frederick L Altice
Journal:  PLoS One       Date:  2009-11-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.